Eine Plattform für die Wissenschaft: Bauingenieurwesen, Architektur und Urbanistik
Eine Plattform für die Wissenschaft: Bauingenieurwesen, Architektur und Urbanistik
Oral Nonviral Gene Delivery for Chronic Protein Replacement Therapy
Efficient nonviral oral gene delivery offers an attractive modality for chronic protein replacement therapy. Herein, the oral delivery of insulin gene is reported by a nonviral vector comprising a copolymer with a high degree of substitution of branched polyethylenimine on chitosan (CS‐g‐bPEI). Protecting the plasmid from gastric acidic degradation and facilitating transport across the gut epithelium, the CS‐g‐bPEI/insulin plasmid DNA nanoparticles (NPs) can achieve systemic transgene expression for days. A single dose of orally administered NPs (600 µg plasmid insulin (pINS)) to diabetic mice can protect the animals from hyperglycemia for more than 10 d. Three repeated administrations spaced over a 10 d interval produce similar glucose‐lowering results with no hepatotoxicity detected. Positron‐emission‐tomography and computed‐tomography images also confirm the glucose utilization by muscle cells. While this work suggests the feasibility of basal therapy for diabetes mellitus, its significance lies in the demonstration of a nonviral oral gene delivery system that can impact chronic protein replacement therapy and DNA vaccination.
Oral Nonviral Gene Delivery for Chronic Protein Replacement Therapy
Efficient nonviral oral gene delivery offers an attractive modality for chronic protein replacement therapy. Herein, the oral delivery of insulin gene is reported by a nonviral vector comprising a copolymer with a high degree of substitution of branched polyethylenimine on chitosan (CS‐g‐bPEI). Protecting the plasmid from gastric acidic degradation and facilitating transport across the gut epithelium, the CS‐g‐bPEI/insulin plasmid DNA nanoparticles (NPs) can achieve systemic transgene expression for days. A single dose of orally administered NPs (600 µg plasmid insulin (pINS)) to diabetic mice can protect the animals from hyperglycemia for more than 10 d. Three repeated administrations spaced over a 10 d interval produce similar glucose‐lowering results with no hepatotoxicity detected. Positron‐emission‐tomography and computed‐tomography images also confirm the glucose utilization by muscle cells. While this work suggests the feasibility of basal therapy for diabetes mellitus, its significance lies in the demonstration of a nonviral oral gene delivery system that can impact chronic protein replacement therapy and DNA vaccination.
Oral Nonviral Gene Delivery for Chronic Protein Replacement Therapy
Lin, Po‐Yen (Autor:in) / Chiu, Ya‐Ling (Autor:in) / Huang, Jing‐Huei (Autor:in) / Chuang, Er‐Yuan (Autor:in) / Mi, Fwu‐Long (Autor:in) / Lin, Kun‐Ju (Autor:in) / Juang, Jyuhn‐Huarng (Autor:in) / Sung, Hsing‐Wen (Autor:in) / Leong, Kam W. (Autor:in)
Advanced Science ; 5
01.08.2018
12 pages
Aufsatz (Zeitschrift)
Elektronische Ressource
Englisch
Delivery of miRNA Using Fe~2O~3 Nanoparticles Capped Polyethyleneimine as a Nonviral Carrier
| British Library Online Contents | 2013
Alternatives to Estrogen Replacement Therapy
| Wiley | 2000
Toilet Replacement Program: Options for Effective Delivery
| British Library Conference Proceedings | 1996
Testosterone Replacement Therapy: The Emperor's New Clothes
British Library Online Contents | 2017